<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962052</url>
  </required_header>
  <id_info>
    <org_study_id>MDL0806</org_study_id>
    <nct_id>NCT00962052</nct_id>
  </id_info>
  <brief_title>Biomarker Discovery and Application in Bladder Cancer</brief_title>
  <official_title>Biomarker Discovery and Application in Bladder Cancer: Identification and Detection of Gene Methylation, Tumor Specific Antigenes Markers of BCG Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Diagnostic Laboratories, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' long-term objective is to research and develop innovative new tests which&#xD;
      diagnostic laboratories can use to 1) detect methylated DNA targets, 2) tumor specific&#xD;
      antigens, and 3) markers of Bacillus Calmette-Guerin (BCG) treatment in patient urine&#xD;
      samples. The investigators plan to detect methylated DNA targets and control targets by&#xD;
      methylation-specific polymerase chain reaction (msPCR) on DNA isolated from urine samples&#xD;
      from bladder cancer positive and negative patients to determine its sensitivity and&#xD;
      specificity in detecting bladder cancer. The investigators plan to use patient sera as a tool&#xD;
      to detect tumor specific antigens expressed by bladder cancer cell lines. Once a bladder&#xD;
      tumor specific protein is identified, the investigators will assess its presence in the urine&#xD;
      of bladder cancer patients and absence in healthy patients by enzyme-linked immunosorbent&#xD;
      assay (ELISA). The investigators plan to use both in vitro models and patient clinical&#xD;
      samples to elucidate the role of bladder epithelial cells in mediating BCG immunotherapy and&#xD;
      identify biomarkers of treatment effectiveness. Once a biomarker is identified, the&#xD;
      investigators will assess its presence in the urine of bladder cancer and absence in healthy&#xD;
      patients.&#xD;
&#xD;
      Once the investigators determine the feasibility of these tests, the investigators will&#xD;
      further perform an extensive clinical study, comparing the tests to existing diagnostic&#xD;
      methods. This study will provide the foundation for FDA approval, which is required for tests&#xD;
      to become widely accepted tools for clinicians to use in bladder cancer diagnosis. The&#xD;
      investigators' tests will improve early detection of bladder cancer, thereby improving&#xD;
      patient health and decrease cancer deaths, a key mission of the National Institutes of&#xD;
      Health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Bladder Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, first void urine, bladder tumors and healthy tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Those currently diagnosed and undergoing treatment for bladder cancer (100).&#xD;
&#xD;
          2. Those currently diagnosed with other urogenital cancers including prostate cancer and&#xD;
             kidney cancer (50).&#xD;
&#xD;
          3. Those currently diagnosed with non-malignant urogenital conditions including urinary&#xD;
             tract infection, interstitial cystitis, and kidney stones for specificity analysis&#xD;
             (50).&#xD;
&#xD;
          4. Healthy control patients (50).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ami Sidi, Prof</last_name>
    <phone>972-3-5028653</phone>
    <email>sidi@wolfson.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pnina Nir, Bsc</last_name>
      <phone>972-3-5028408</phone>
      <email>pninanir@wolfson.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ami Sidi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>September 12, 2010</last_update_submitted>
  <last_update_submitted_qc>September 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof Ami Sidi</name_title>
    <organization>Wolfson M.C</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

